Strategic Collaboration Vibalogics is now part of Recipharm and recently announced a strategic collaboration with Fusix Biotech to support development and manufacturing of next-generation cancer immunotherapies using oncolytic virus technology, signaling expanded capacity and joint go-to-market opportunities for viral therapies.

Virotherapy Focus The company specializes in virotherapy development and GMP manufacturing, including viral vectors, oncolytic viruses, gene therapy, vaccines, and related analytic and fill-finish services, presenting a strong value proposition for clients pursuing early to late-stage virotherapy programs.

Clinical to Commercial Readiness Service offerings span technical transfer, development, manufacturing, testing, formulation, fill finish, and stability studies, enabling clients to move from clinical development toward scalable commercial production within a single partner ecosystem.

Global Regulatory & Quality Emphasizing robust quality systems and global regulatory compliance provides a selling point for customers seeking reliable CDMO capabilities to de-risk regulatory timelines and ensure consistent GMP compliance across batches.

Mid-Sized Growth Potential Revenue in the lower to mid multi-million range and a lean team indicate nimble collaboration potential with larger CRO/CDMO ecosystems while offering specialized virotherapy manufacturing capabilities that complement bigger players’ portfolios.